VC and Investment
Biotechnology
US biotech major Moderna plans to raise $2 billion through a private placement of convertible senior notes due 2032, offered to qualified institutional buyers under Rule 144A. Initial purchasers will get a 13-day option to take up to $300 million of additional notes, which would lift the total to $2.3 billion. 28 August 2026
Today's issue
Refine search
Biotechnology
US venture firm MBX Capital has crossed $100 million in cumulative capital commitments to invest in early-stage biotech and health technology companies developing innovations that prevent and cure disease. 17 December 2025
Biotechnology
California, USA-based clinical-stage biopharmaceutical company Aeovian Pharmaceuticals revealed it has closed an oversubscribed $55 million Series B financing that will fund completion of a Phase II proof-of-concept study for its lead development candidate, AV078, in tuberous sclerosis complex (TSC)-related refractory epilepsy. 17 December 2025
Biotechnology
US clinical-stage US autoimmune drug developer Kyverna Therapeutics saw its shares leap more than 23% to $10.82 after its announced positive top-line data from KYSA-8, its registrational Phase II trial of mivocabtagene autoleucel (‘miv-cel’), formerly KYV-101), a fully human, autologous CD19-targeting CAR T-cell therapy with CD28 co-stimulation, in stiff person syndrome (SPS). 16 December 2025
Biotechnology
Link Cell Therapies, an oncology cell therapy company, has announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson. 15 December 2025
Biotechnology
New US legislation, backed by trade group Biotechnology Innovation Organization (BIO), to free up capital for small innovative firms by removing regulatory barriers for both companies and investors passed the House of Representative on December 11. 15 December 2025
Biotechnology
One of the biggest challenges to the cell and gene therapy (CGT) landscape over the last couple of years has been the reduction in venture financing from $7.5 billion in 2021 to $3.3 billion in 2024. 15 December 2025
Biotechnology
California-based Tenaya Therapeutics, a biotech seeking to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, has announced the pricing of a $60 million public offering. 15 December 2025
Pharmaceutical
British pharma major AstraZeneca has joined a near-$100 million series A and A+ financing round for Syneron Bio, a biotechnology startup focused on macrocyclic peptide therapies for oncology and chronic diseases. 12 December 2025
Pharmaceutical
Danish biotech Sidera Bio has raised about 700 million kroner ($109 million) in a series A financing, one of the largest early-stage biotech rounds ever completed in Denmark. Investors include Novo Holdings, Forbion, RA Capital Healthcare Fund and Gilde Healthcare. 12 December 2025
Pharmaceutical
Medra, a US company developing the first platform for physical AI scientists, has announced a $52 million Series A financing. 12 December 2025
Biotechnology
California, USA-based biotech Prolynx, which is developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, has announced the closing of a $70 million Series A financing and the appointment of industry veteran Chris Boulton as chief executive (CEO). 12 December 2025
Pharmaceutical
German biotech Disco Pharmaceuticals has appointed Mark Manfredi as chief executive and closed a 36 million euro ($39 million) seed round to advance its surfaceome-targeted pipeline. The financing was co-led by Ackermans & van Haaren and NRW.Bank with backing from Sofinnova Partners, AbbVie Ventures, M Ventures and Panakes Partners. 11 December 2025
Pharmaceutical
PsiThera has closed a $47.5 million series A round to advance oral therapies for immune and inflammatory diseases. The company also named former Seres Therapeutics chief executive Eric Shaff as chief executive. 11 December 2025
Pharmaceutical
Privately-held BlossomHill Therapeutics, a US biopharma focused on the design and development of next-generation medicines for cancer, has announced the closing of an $84 million Series B extension, bringing total capital raised by the company to $257 million to date. 10 December 2025
Biotechnology
EpilepsyGTx’s $33 million Series A to advance single dose gene therapy for focal refractory epilepsy
UK-based EpilepsyGTx, a biotech focused on research and development of gene therapies to treat refractory epilepsy, has raised $33 million in a Series A financing to advance its lead program EPY201 through Phase I/IIa trials. 10 December 2025
Biotechnology
Clinical-stage biotech D3 Bio announced the completion of a $108 million Series B financing round, adding to the continuous flow of venture capital interest in Chinese companies. 10 December 2025
Biotechnology
Chinese biotech dominance and opportunities for Western companies to stay competitive have been highlighted in surveys released by clinical research organization ICON. 10 December 2025
Biotechnology
Sanegene Bio has raised more than $110 million in a series B round to move its RNAi programs toward registration studies and broaden development across metabolic, cardiovascular and autoimmune diseases. The financing comes as global RNA-based medicines gain momentum and investors show renewed confidence in advanced delivery platforms. 9 December 2025
Biotechnology
The cell and gene therapy (CGT) sector is undergoing a transition as companies navigate a more selective and strategy-driven funding landscape, according to an analysis by the pharma strategic intelligence team at and pharma analytics company. GlobalData. 9 December 2025
Biotechnology
Shanghai-based biotech OTR Therapeutics has emerged from stealth and announced the successful completion of a $100 million Series A financing closed in June 2025. 8 December 2025
Biotechnology
USA-based biotech Superluminal Medicines has closed an oversubscribed $60 million series B, money earmarked for moving its lead obesity candidate into human testing before the end of 2026. The round was led by BVF Partners, with Deep Track Capital and Perceptive Advisors joining as first-time backers. 4 September 2026
Biotechnology
USA-based biotech company Typewriter Therapeutics, which also runs a Japanese arm, came out of stealth on Wednesday with $56 million in series A financing. The round was led by US venture firm AN Venture Partners and US investment firm RA Capital Management, with Japanese venture firm ANRI, Gemseki and SBI US Gateway Fund also taking part. 3 September 2026
Pharmaceutical
The USA's Advanced Research Projects Agency for Health (ARPA-H) has selected five teams to build the equipment needed to make individualized RNA medicines close to the patient, awarding contracts worth up to $125 million in research and development funding. 2 September 2026
Biotechnology
French biotech firm Inventiva has appointed Chris Benecchi as chief operating officer, completing its leadership team roughly one quarter before the trial result that will decide the company's direction. Topline data from the pivotal Phase III NATiV3 study of lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH) are expected in the final quarter of 2026. 2 September 2026
Biotechnology
USA-based infectious disease biotech firm EIT Pharma has closed an oversubscribed $35 million series A round, led by Propel Bio Partners with participation from Good Ventures, Arrowtown and others. The Kirkland, Washington company said the money will principally support its lead candidate, the oral chronic hepatitis D therapy lonafarnib. 1 September 2026
Pharmaceutical
US specialty pharma company Quoin Pharmaceuticals on Friday said it has entered into a securities purchase agreement to raise up to approximately $50.0 million in gross proceeds. 29 August 2026
Biotechnology
ProFound Therapeutics, a Flagship Pioneering company based in Cambridge, Massachusetts, has received an investment commitment of up to $35 million from the Gates Foundation, including an initial $20 million payment, to support drug target and biomarker discovery for preeclampsia and eclampsia. 28 August 2026
Biotechnology
US biotech major Moderna plans to raise $2 billion through a private placement of convertible senior notes due 2032, offered to qualified institutional buyers under Rule 144A. Initial purchasers will get a 13-day option to take up to $300 million of additional notes, which would lift the total to $2.3 billion. 28 August 2026
Biotechnology
Redx Pharma, a UK based, privately-held clinical-stage biotechnology, today announced completion of its Series A financing of $36 million. 27 August 2026
Biotechnology
German cancer specialist Immatics today announced that it has agreed to sell 12,945,916 ordinary shares at $8.69 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 4,315,304 ordinary shares at a purchase price of $8.689 per pre-funded warrant. 25 August 2026
Biotechnology
German biotech Revier Therapeutics has launched operations following the close of a 6 million euros ($6.45 million) seed financing round, the Heidelberg-based company announced Tuesday. 25 August 2026
Biotechnology
Canada-based Edesa Biotech has priced an underwritten public offering expected to generate approximately $25 million in gross proceeds. The company’s shares slumped 17.2% to $4.76 following the announcement. 21 August 2026
Biotechnology
Network Bio, a Palo Alto, California-based biotechnology company building AI models trained on human biological data, launched Wednesday with $50 million in financing from investors including Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund and JSL Health Capital. 20 August 2026
Biotechnology
Dutch clinical-stage biotech Kynexis today announced the closing of a 40 million euros ($46.3 million) Series A extension bringing total Series A financing to 97 million euros ($110 million). 19 August 2026
Pharmaceutical
Invesco Mutual Fund has announced the launch of Invesco India Pharma and Healthcare Fund - an open-ended equity scheme investing in pharmaceutical, healthcare and allied sectors. 19 August 2026
Pharmaceutical
USA-based bioanalysis firm Dash Bio has raised $30 million in a series A round led by Oak HC/FT, money it will spend on a laboratory that hands much of drug safety and efficacy testing to robots. Existing backers Freestyle Capital and Swift Ventures also took part. The round takes total funding at the Waltham, Massachusetts company to $47.5 million. 19 August 2026
Biotechnology
San Diego, USA-based Zentalis Pharmaceuticals has announced the successful closing of its underwritten public offering, raising around $92.6 million in gross proceeds before deducting fees and expenses. 19 August 2026
Pharmaceutical
USA-based Femasys, a biomedical innovator focused on fertility and permanent birth control solutions, has secured $30 million in financing, with potential proceeds reaching up to $90 million upon the full cash exercise of warrants. 18 August 2026
Biotechnology
USA-based Khartis Therapeutics has come out of stealth with $95 million raised to date and a plan to develop an oral pill for thyroid eye disease (TED), a market currently served only by antibodies given by intravenous infusion. The San Diego biotech announced the debut on Thursday. 14 August 2026
Biotechnology
USA-based CNS specialist MapLight Therapeutics announced it has secured approximately $150 million in gross proceeds through a private placement financing (PIPE). 13 August 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze